|Bid||254.82 x 200|
|Ask||271.43 x 100|
|Day's Range||271.20 - 279.40|
|52 Week Range||225.68 - 333.65|
|PE Ratio (TTM)||16.99|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 84. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)